col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world

58 Results       Page 1

American Chemical Society: ACS Pharmacology & Translational Science
  original article Date Title Authors   All Authors
1 [GO] 2022―Jun―22 Enzyme Nanoscale Interactions with Manganese Zinc Sulfide Give Insight into Potential Antiviral Mechanisms and SARS-CoV-2 Inhibition Robert K. DeLong, Hanah Huber, Cesar Aparicio-Lopez, Abeera Bhatti, Ryan Swanson, Tej B. Shrestha, Natasha N. Gaudreault
2 [GO] 2022―May―23 Different Aspects of Emetine’s Capabilities as a Highly Potent SARS-CoV-2 Inhibitor against COVID-19 Mehdi Valipour
3 [GO] 2022―Apr―04 Hit Expansion of a Noncovalent SARS-CoV-2 Main Protease Inhibitor Jens Glaser, Ada Sedova, Stephanie Galanie, Daniel W. Kneller, Russell B. Davidson, Elvis Maradzike, et al. (+12)
4 [GO] 2022―Apr―01 Natural Compounds Inhibit SARS-CoV-2 nsp13 Unwinding and ATPase Enzyme Activities Angela Corona, Krzysztof Wycisk, Carmine Talarico, Candida Manelfi, Jessica Milia, Rolando Cannalire, et al. (+8)
5 [GO] 2022―Feb―14 Allosteric Site of ACE-2 as a Drug Target for COVID-19 Kunal Dutta
6 [GO] 2022―Jan―25 Experimental Model of Pulmonary Inflammation Induced by SARS-CoV-2 Spike Protein and Endotoxin Manoj Puthia, Lloyd Tanner, Ganna Petruk, Artur Schmidtchen
7 [GO] 2022―Jan―24 Validation and Invalidation of SARS-CoV-2 Papain-like Protease Inhibitors Chunlong Ma, Jun Wang
8 [GO] 2022―Jan―03 SARS-CoV-2 Nucleocapsid Protein TR-FRET Assay Amenable to High Throughput Screening Kirill Gorshkov, Desarey Morales Vasquez, Kevin Chiem, Chengjin Ye, Bruce Nguyen Tran, Juan Carlos de la Torre, et al. (+4)
9 [GO] 2021―Sep―17 Hybrid In Silico Approach Reveals Novel Inhibitors of Multiple SARS-CoV-2 Variants Sankalp Jain, Daniel C. Talley, Bolormaa Baljinnyam, Jun Choe, Quinlin Hanson, Wei Zhu, et al. (+9)
10 [GO] 2021―Sep―06 Inhibition of Severe Acute Respiratory Syndrome Coronavirus 2 Replication by Hypertonic Saline Solution in Lung and Kidney Epithelial Cells Rafael R. G. Machado, Talita Glaser, Danielle B. Araujo, Lyvia Lintzmaier Petiz, Danielle B. L. Oliveira, Giuliana S. Durigon, et al. (+6)
11 [GO] 2021―Jul―29 Identification of Novel Neutralizing Monoclonal Antibodies against SARS-CoV-2 Spike Glycoprotein Devivasha Bordoloi, Ziyang Xu, Michelle Ho, Mansi Purwar, Pratik Bhojnagarwala, Joel Cassel, et al. (+18)
12 [GO] 2021―Jun―09 Rational Design of Hybrid SARS-CoV-2 Main Protease Inhibitors Guided by the Superimposed Cocrystal Structures with the Peptidomimetic Inhibitors GC-376, Telaprevir, and Boceprevir Zilei Xia, Michael Sacco, Yanmei Hu, Chunlong Ma, Xiangzhi Meng, Fushun Zhang, et al. (+4)
13 [GO] 2021―Apr―29 Correction to “Synergistic Inhibition of SARS-CoV-2 Replication Using Disulfiram/Ebselen and Remdesivir” Ting Chen, Cheng-Yin Fei, Yi-Ping Chen, Karen Sargsyan, Jian-Jong Liang, Chun-Che Liao, et al. (+4)
14 [GO] 2021―Apr―16 Identification of Novel MicroRNAs Targeting SARS-CoV-2 through the Regulation of TMPRSS2/PI3K/AKT/PTEN Alignment in Lung Cancer: An in Silico Analysis Debasmita Mukhopadhyay, Nour AlSawaftah, Ghaleb A Husseini
15 [GO] 2021―Apr―02 Discovery of TMPRSS2 Inhibitors from Virtual Screening as a Potential Treatment of COVID-19 Xin Hu, Jonathan H. Shrimp, Hui Guo, Miao Xu, Catherine Z. Chen, Wei Zhu, et al. (+6)
16 [GO] 2021―Mar―26 Synergistic Inhibition of SARS-CoV-2 Replication Using Disulfiram/Ebselen and Remdesivir Ting Chen, Cheng-Yin Fei, Yi-Ping Chen, Karen Sargsyan, Chun-Ping Chang, Hanna S. Yuan, Carmay Lim
17 [GO] 2021―Mar―22 Repurposing Quinoline and Artemisinin Antimalarials as Therapeutics for SARS-CoV-2: Rationale and Implications Tessa M. Firestone, Opeoluwa O. Oyewole, St Patrick Reid, Caroline L. Ng
18 [GO] 2021―Mar―19 COVID-19: Is There a Link between Alcohol Abuse and SARS-CoV-2-Induced Severe Neurological Manifestations? Jibran Sualeh Muhammad, Ruqaiyyah Siddiqui, Naveed Ahmed Khan
19 [GO] 2021―Mar―17 A Blueprint for High Affinity SARS-CoV-2 Mpro Inhibitors from Activity-Based Compound Library Screening Guided by Analysis of Protein Dynamics Jonas Gossen, Simone Albani, Anton Hanke, Benjamin P. Joseph, Cathrine Bergh, Maria Kuzikov, et al. (+14)
20 [GO] 2021―Mar―11 Identification of Inhibitors of SARS-CoV-2 3CL-Pro Enzymatic Activity Using a Small Molecule in Vitro Repurposing Screen Maria Kuzikov, Elisa Costanzi, Jeanette Reinshagen, Francesca Esposito, Laura Vangeel, Markus Wolf, et al. (+27)
21 [GO] 2021―Mar―04 COVID-19: Does SARS-CoV-2 Modulate Acanthamoeba Epigenetics to Enhance Survival and Transmission in the Environment? Jibran Sualeh Muhammad, Ruqaiyyah Siddiqui, Naveed Ahmed Khan
22 [GO] 2021―Mar―01 Toward the Next-Generation COVID-19 Vaccines That Circumvent Antigenic Drift while Defusing Viral Infection Ariel Fernández
23 [GO] 2021―Feb―05 SARS-CoV-2 Glycosylation Suggests That Vaccines Should Have Adopted the S1 Subunit as Antigen Ariel Fernández
24 [GO] 2021―Jan―29 Docking Prediction of Levodopa in the Receptor Binding Domain of Spike Protein of SARS-CoV-2 Abdul Mannan Baig, Areeba Khaleeq, Hira Syeda, Noor Bibi
25 [GO] 2021―Jan―21 Glycosylation of SARS-CoV-2 Steers Evolutionary Outcomes in the Postvaccination Phase Ariel Fernández
26 [GO] 2021―Jan―15 Diagnostic, Prognostic, and Therapeutic Use of Radiopharmaceuticals in the Context of SARS-CoV-2 Roger M. Pallares, Rebecca J. Abergel
27 [GO] 2021―Jan―10 SARS-CoV-2, Hypoxia, and Calcium Signaling: The Consequences and Therapeutic Options Chhanda Charan Danta
28 [GO] 2020―Dec―31 COVID-19 Evolution in the Post-Vaccination Phase: Endemic or Extinct? Ariel Fernández
29 [GO] 2020―Dec―30 Innate Immunity Plays a Key Role in Controlling Viral Load in COVID-19: Mechanistic Insights from a Whole-Body Infection Dynamics Model Prashant Dogra, Javier Ruiz-Ramírez, Kavya Sinha, Joseph D. Butner, Maria J. Peláez, Manmeet Rawat, et al. (+6)
30 [GO] 2020―Dec―29 Antibacterial and Antiviral Functional Materials: Chemistry and Biological Activity toward Tackling COVID-19-like Pandemics Bhuvaneshwari Balasubramaniam, Sudhir Ranjan, Mohit Saraf, Prasenjit Kar, Surya Pratap Singh, Vijay Kumar Thakur, et al. (+2)
31 [GO] 2020―Dec―12 Treatment with an Anti-CK2 Synthetic Peptide Improves Clinical Response in COVID-19 Patients with Pneumonia. A Randomized and Controlled Clinical Trial Leticia R. Cruz, Idania Baladrón, Aliusha Rittoles, Pablo A. Díaz, Carmen Valenzuela, Raúl Santana, et al. (+19)
32 [GO] 2020―Dec―09 Identification of Novel MicroRNAs as Promising Therapeutics for SARS-CoV-2 by Regulating the EGFR-ADAM17 Axis: An In Silico Analysis Debasmita Mukhopadhyay, Nour AlSawaftah, Ghaleb A. Husseini
33 [GO] 2020―Dec―01 Clinically Approved Antiviral Drug in an Orally Administrable Nanoparticle for COVID-19 Bapurao Surnar, Mohammad Z. Kamran, Anuj S. Shah, Shanta Dhar
34 [GO] 2020―Nov―17 Targeting ACE2-RBD Interaction as a Platform for COVID-19 Therapeutics: Development and Drug-Repurposing Screen of an AlphaLISA Proximity Assay Quinlin M. Hanson, Kelli M. Wilson, Min Shen, Zina Itkin, Richard T. Eastman, Paul Shinn, Matthew D. Hall
35 [GO] 2020―Nov―11 Clinical HDAC Inhibitors Are Effective Drugs to Prevent the Entry of SARS-CoV2 Ke Liu, Rongfeng Zou, Wenqiang Cui, Meiqing Li, Xueying Wang, Junlin Dong, et al. (+8)
36 [GO] 2020―Nov―07 Probing the Dynamic Structure-Function and Structure-Free Energy Relationships of the Coronavirus Main Protease with Biodynamics Theory Hongbin Wan, Vibhas Aravamuthan, Robert A. Pearlstein
37 [GO] 2020―Nov―03 Docking Prediction of Amantadine in the Receptor Binding Domain of Spike Protein of SARS-CoV-2 Abdul Mannan Baig, Areeba Khaleeq, Hira Syeda
38 [GO] 2020―Oct―19 Identifying SARS-CoV-2 Entry Inhibitors through Drug Repurposing Screens of SARS-S and MERS-S Pseudotyped Particles Catherine Z. Chen, Miao Xu, Manisha Pradhan, Kirill Gorshkov, Jennifer D. Petersen, Marco R. Straus, et al. (+9)
39 [GO] 2020―Oct―15 Defusing SARS-CoV-2: Emergency Brakes in a Vaccine Failure Scenario Ariel Fernández
40 [GO] 2020―Oct―14 Virtual and In Vitro Antiviral Screening Revive Therapeutic Drugs for COVID-19 Giovanni Bocci, Steven B. Bradfute, Chunyan Ye, Matthew J. Garcia, Jyothi Parvathareddy, Walter Reichard, et al. (+7)
41 [GO] 2020―Oct―09 Ebselen, Disulfiram, Carmofur, PX-12, Tideglusib, and Shikonin Are Nonspecific Promiscuous SARS-CoV-2 Main Protease Inhibitors Chunlong Ma, Yanmei Hu, Julia Alma Townsend, Panagiotis I. Lagarias, Michael Thomas Marty, Antonios Kolocouris, Jun Wang
42 [GO] 2020―Oct―09 Development of a High-Throughput Homogeneous AlphaLISA Drug Screening Assay for the Detection of SARS-CoV-2 Nucleocapsid Kirill Gorshkov, Catherine Z. Chen, Miao Xu, Juan Carlos de la Torre, Luis Martinez-Sobrido, Thomas Moran, Wei Zheng
43 [GO] 2020―Sep―30 Helminths and COVID-19 Co-Infections: A Neglected Critical Challenge Amir Abdoli
44 [GO] 2020―Sep―28 Ivermectin, Famotidine, and Doxycycline: A Suggested Combinatorial Therapeutic for the Treatment of COVID-19 Parth Sarthi Sen Gupta, Malay Kumar Rana
45 [GO] 2020―Sep―28 Heme/Hemeoxygenase-1 System Is a Potential Therapeutic Intervention for COVID-19 Patients with Severe Complications Biplab K Maiti
46 [GO] 2020―Sep―18 SARS-CoV-2 vaccine development: An overview and perspectives Yi Liu, Kai Wang, Tarik F. Massoud, Ramasamy Paulmurugan
47 [GO] 2020―Sep―15 Achilles’ Heel of SARS-CoV-2 Structure Ariel Fernández
48 [GO] 2020―Sep―08 Can SARS-CoV-2 Accumulate Mutations in the S-Protein to Increase Pathogenicity? Aditya K. Padhi, Timir Tripathi
49 [GO] 2020―Sep―07 An Enzymatic TMPRSS2 Assay for Assessment of Clinical Candidates and Discovery of Inhibitors as Potential Treatment of COVID-19 Jonathan H. Shrimp, Stephen C. Kales, Philip E. Sanderson, Anton Simeonov, Min Shen, Matthew D. Hall
50 [GO] 2020―Sep―04 Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-throughput Screening Wei Zhu, Miao Xu, Catherine Z. Chen, Hui Guo, Min Shen, Xin Hu, et al. (+4)
51 [GO] 2020―Sep―01 Therapeutically Targeted Destabilization of the Quaternary Structure of the Spike Protein in the Dominant G614 Strain of SARS-CoV-2 Ariel Fernández
52 [GO] 2020―Aug―27 Double-Barreled CRISPR Technology as a Novel Treatment Strategy For COVID-19 Dhanusha Nalawansha, Kusal Samarasinghe
53 [GO] 2020―Aug―18 Dipeptidyl Peptidase-4: A Potential Therapeutic Target in Diabetic Kidney Disease with SARS-CoV-2 Infection Chhanda Charan Danta
54 [GO] 2020―Aug―04 Can Papain-like Protease Inhibitors Halt SARS-CoV-2 Replication? Biplab K Maiti
55 [GO] 2020―Jul―30 Potential therapeutic agents and associated bioassay data for COVID-19 and related human coronavirus infections Qiongqiong Zhou, Junko Kato-Weinstein, Yingzhu Li, Yi Deng, Roger Granet, Linda Garner, et al. (+4)
56 [GO] 2020―Jul―24 Potential Role of Peptide-Based Antiviral Therapy Against SARS-CoV-2 Infection Biplab K. Maiti
57 [GO] 2020―Jul―23 SARS-CoV-2 receptor ACE2 is enriched in a subpopulation of mouse tongue epithelial cells in non-gustatory papillae, but not in taste buds or embryonic oral epithelium Zhonghou Wang, Jingqi Zhou, Brett Marshall, Romdhane Rekaya, Kaixiong Ye, Hong-Xiang Liu
58 [GO] 2020―Jun―16 The Potential of Antimicrobial Peptides as an Antiviral Therapy against COVID-19 Sherif Elnagdy, Maha AlKhazindar

58 Results       Page 1


Last change 2022―Feb―03 17:06:14 UTC

© Daten-Quadrat 2022       Done in 0.038 sec